Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

Thomas, Reji; Çetin, Mesut; Baker, Glen B.; Dursun, Serdar

doi:10.5455/bcp.20161027122045

Cited by 4 publications

(3 citation statements)

References 9 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psychedelic-assisted psychotherapy refers to pairing psychedelic substances with psychotherapeutic interventions to maximize therapeutic outcomes. Research indicates that psychedelics and substances that induce non-ordinary states of consciousness can provide a significant reduction in symptoms, so much so that the U.S. Federal Drug Administration (FDA) has granted some medications Breakthrough Therapy designation (e.g., Thomas et al, 2016). This means that the substances have shown preliminary clinical evidence demonstrating that the drug may have an advantage over the currently available therapies (Federal Drug Administration [FDA], 2018).…”

Section: Introduction To Psychedelic-assisted Therapiesmentioning

confidence: 99%

Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination

Halstead¹,

Reed²,

Krause

et al. 2021

Clinical Case Studies

View full text Add to dashboard Cite

Current research suggests that ketamine-assisted psychotherapy has benefit for the treatment of mental disorders. We report on the results of ketamine-assisted intensive outpatient psychotherapeutic treatment of a client with treatment-resistant, posttraumatic stress disorder (PTSD) as a result of experiences of racism and childhood sexual abuse. The client’s presenting symptoms included hypervigilance, social avoidance, feelings of hopelessness, and intense recollections. These symptoms impacted all areas of daily functioning. Psychoeducation was provided on how untreated intergenerational trauma, compounded by additional traumatic experiences, potentiated the client’s experience of PTSD and subsequent maladaptive coping mechanisms. Ketamine was administered four times over a 13-day span as an off-label, adjunct to psychotherapy. Therapeutic interventions and orientations utilized were mindfulness-based cognitive therapy (MBCT) and functional analytic psychotherapy (FAP). New skills were obtained in helping the client respond effectively to negative self-talk, catastrophic thinking, and feelings of helplessness. Treatment led to a significant reduction in symptoms after completion of the program, with gains maintained 4 months post-treatment. This case study demonstrates the effective use of ketamine as an adjunct to psychotherapy in treatment-resistant PTSD.

show abstract

Section: Introduction To Psychedelic-assisted Therapiesmentioning

confidence: 99%

Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination

Halstead¹,

Reed²,

Krause

et al. 2021

Clinical Case Studies

View full text Add to dashboard Cite

show abstract

“…The same may apply to esketamine, and could explain the reason for its rapid onset of action, and the continuation of its effects even after elimination of the drug from the body [27,30]. The intranasal form of esketamine has multiple positive benefits as opposed to other modes of administration, as it is less painful and invasive, while also having a greater bioavailability than oral form [30]. Figure 2 shows the proposed mechanism of action of esketamine.…”

Section: Pharmacological Basismentioning

confidence: 97%

“…Studies show that ketamine has a more direct stimulating action on BDNF and mTOR compared to oral antidepressants [ 27 , 29 ]. The same may apply to esketamine, and could explain the reason for its rapid onset of action, and the continuation of its effects even after elimination of the drug from the body [ 27 , 30 ]. The intranasal form of esketamine has multiple positive benefits as opposed to other modes of administration, as it is less painful and invasive, while also having a greater bioavailability than oral form [ 30 ].…”

Section: Reviewmentioning

confidence: 99%